Aktie A2QFV3 JW (CAYMAN) THERAPEUTICS CO. LTD
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen JW (Cayman) Therapeutics Co. Ltd

Aktien

A2QFV3

KYG5210T1040

2126

Markt geschlossen - Hong Kong S.E.
Andere Börsenplätze
 10:08:22 10.05.2024 		% 5 Tage % 1. Jan.
2,43 HKD +29,95 % Intraday Chart für JW (Cayman) Therapeutics Co. Ltd +27,89 % +7,52 %
20.03. JW (Cayman) Therapeutics schrumpft Verlust im Geschäftsjahr 2023 MT
20.03. JW (Cayman) Therapeutics Co. Ltd. meldet Ergebnis für das Geschäftsjahr bis zum 31. Dezember 2023 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
JW (Cayman) Therapeutics Shrinks Loss in Fiscal 2023
JW Therapeutics Co. Ltd Reports Earnings Results for the Full Year Ended December 31, 2023
China Regulator Accepts JK Therapeutics' Supplemental License Application for Lymphoma Therapy
JW Therapeutics Announces NMPA Acceptance of the Supplemental Biological License Application for Carteyva in Patients with Relapsed or Refractory Mantle Cell Lymphoma
JW (Cayman) Therapeutics Signs Collaboration Deal for Development of Autoimmune Disease Treatment
JW Therapeutics Announces Exclusive Collaboration with 2Seventy Bio for Autoimmune Disease Car-T Therapy
JW Therapeutics CFO Resigns
JW Therapeutics Co. Ltd Announces Resignation of Xin Fu as Chief Financial Officer
JW (Cayman) Therapeutics to Expand Strategic Alliance with Cell and Gene Therapy Firm
2Seventy Bio, Inc. and Jw Therapeutics Announce Intent to Expand Strategic Partnership to Accelerate the Research and Development of T Cell-Based Immunotherapies and Autoimmune Therapies
JW Therapeutics Co. Ltd Announces Board Changes
JW Therapeutics' H1 Attributable Loss Narrows on Higher Revenue
JW Therapeutics Co. Ltd Reports Earnings Results for the Half Year Ended June 30, 2023
JW (Cayman) Therapeutics to Buy Viral Vector from Substantial Shareholder
China Gives Investigational New Drug Clearance to JW Therapeutics' Anti-Lupus Injection; Shares Rise 7%
JW Therapeutics Announces IND Approval for the Clinical Trial of Relma-cel in Patients with Moderately or Severely Refractory Systemic Lupus Erythematosus
JW Therapeutics' 2022 Loss Widens
JW Therapeutics Co. Ltd Reports Earnings Results for the Full Year Ended December 31, 2022
JW (Cayman) Therapeutics Initiates Clinical Study for B-Cell Lymphoma Injection
JW Therapeutics Co. Ltd. Announces Initiation of Clinical Study of Carteyva® in First-Line Treatment in Patients with High-Risk Large B-Cell Lymphoma
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2QFV3 Aktie
  4. Nachrichten JW (Cayman) Therapeutics Co. Ltd
  5. Andere Sprachen